Compare C3.ai Inc (AI) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? C3.ai Inc trades at $10.11 (market cap $1.65B), while Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 17.9× C3.ai Inc's market cap, and C3.ai Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| AI | ALNY | |
|---|---|---|
Market Cap | $1.65B | $29.60B |
Sector | Technology | Health |
52-Week High | $19.66 | $491.22 |
52-Week Low | $7.76 | $205.48 |
Enterprise Value | $1.08B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.125, down 2.64% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported revenue of $389.06 million in 2025 but a net loss of $288.70 million, reflecting persistent unprofitability. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research (Business Wire, August 10, 2026), though CFO share sales and mixed earnings beats add complexity.
The stock faces significant fundamental challenges with negative margins and cash flow, but analyst consensus is mixed with a $10.20 price target near current levels. Investment opportunity hinges on AI platform adoption growth, while risks include sustained losses, competitive pressure, and high valuation multiples absent earnings.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
